lanthanum carbonate has been researched along with Chronic Kidney Failure in 155 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 67 (43.23) | 29.6817 |
| 2010's | 82 (52.90) | 24.3611 |
| 2020's | 6 (3.87) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Cui, X; Jiang, S; Liu, L; Tang, X | 1 |
| Chang, X; Li, M; Shang, S; Xu, W; Yu, M; Zhou, Q | 1 |
| Kano, M; Katoh, M; Okabe, T; Okazaki, R; Tanaka, Y; Toyoda, H; Ueno, M | 1 |
| Fujikawa, K; Hiroyoshi, T; Isoyama, N; Kuro-O, M; Matsuyama, H; Miura, Y; Nagata, Y; Nakamura, K | 1 |
| Badve, SV; Elder, GJ; Hawley, CM; Lioufas, NM; Pascoe, EM; Pedagogos, E; Toussaint, ND; Valks, A | 1 |
| Iwamuro, M; Okada, H; Tanaka, T; Urata, H | 1 |
| Acedo, IE; de la Mata, DM; Díaz, CC; Irurita, VJ; San Martín, LZ; Santos, ÁP | 1 |
| Kobayashi, M; Takeda, H; Tatemichi, S; Yaguchi, A | 1 |
| St Peter, WL; Wazny, LD; Weinhandl, ED | 1 |
| Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Wada, T | 1 |
| Iwamuro, M; Kawahara, Y; Kawano, S; Kimoto, K; Okada, H; Tanaka, T; Urata, H | 1 |
| Achenbach, H; Hall, G; Hutchison, A; Thadhani, R; Vergani, A; Whelton, A; Wu, J | 1 |
| Li, H; Lin, Z; Xie, W; Zhou, T | 1 |
| Awad, C; Gilkison, K; Shaw, E | 1 |
| Fischer, M; Gork, I; Shavit, MM | 1 |
| Oguri, N; Shiratori, Y | 1 |
| Ando, R; Chida, Y; Inoue, A; Ishida, Y; Iwamoto, S; Kikuchi, K; Kimura, H; Ohtsuka, M; Sato, H; Tachibana, K; Takayama, M; Yamada, K; Yoshizaki, Y | 1 |
| Furui, H; Gotoh, J; Hattori, M; Horie, T; Iida, J; Kawamura, A; Kukita, K; Meguro, J; Onodera, K; Tamaki, T; Tsuchihashi, S; Yonekawa, M | 1 |
| Hasegawa, Y; Kamo, Y; Kikuchi, N; Matsuda, E; Sekino, H; Sekino, M; Takeuchi, K | 1 |
| Hong, Z; Ishizu, T; Kaneko, Y; Matsunaga, T; Taru, Y | 1 |
| Kabaya, T; Mitsuhashi, T; Miyajima, S; Nitta, K; Ogawa, T; Ohba, T; Otsuka, K; Shizuku, J; Takahashi, M; Takahashi, N; Yamashita, T | 1 |
| Guo, H; Tang, S; Zhang, S; Zhang, X | 1 |
| Di, B; Gao, X; Huang, W; Liu, J; Tang, Y; Zhang, F | 1 |
| Copley, JB; Keith, MS; Preston, P; Wilson, RJ | 2 |
| Kurita, N; Uchihara, H | 1 |
| Galani, VJ; Prajapati, VA; Shah, PR | 1 |
| Fukuda, M; Ikeda, Y; Kishi, T; Miyazono, M; Nonaka, Y; Sanai, T; Sato, S; Takashima, T; Yoshizaki, M | 1 |
| Ando, R; Chida, Y; Inagaki, Y; Inoue, A; Ishida, Y; Iwamoto, S; Kikuchi, K; Kimura, H; Ohnishi, T; Ohtsuka, M; Tachibana, K; Takayama, M; Yama, S; Yamada, K | 1 |
| Hara, K; Kishi, Y; Kurosawa, N; Obara, Y; Takada, D; Yamashiro, H | 1 |
| Kumagai, J; Mukai, I; Takahashi, N; Tsuchiya, S; Yoshizawa, T | 1 |
| Barrientos Delgado, A; Berenguer Guirado, R; Florido García, M; Palacios Pérez, A | 1 |
| Brunelli, SM; Copley, JB; Keith, MS; Sibbel, S; Wilson, RJ | 1 |
| Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Suzuki, H | 1 |
| Kitazono, T; Noguchi, H; Ooboshi, H; Tatsumoto, N; Tokumoto, M; Tsuruya, K; Yamada, S | 1 |
| Iwatani, Y; Masumoto, AR; Mima, T; Moribata, MK; Nakashima, YM; Negi, S; Ohya, M; Shigematsu, T; Tatsuta, K; Yamanaka, S | 1 |
| Burnier, M; Funk, F; Maillard, M; Malluche, HH; Phan, O; Stehle, JC | 1 |
| Haratake, J; Ohtani, A; Yasunaga, C | 1 |
| Iwamuro, M; Okada, H; Sakae, H | 1 |
| Abrisqueta Carrión, J; Ibáñez Cánovas, N; Luján Mompeán, JA; Parrilla Paricio, P; Ruiz Pardo, J | 1 |
| Copley, JB; Garafola, S; Hutchison, AJ; Wilson, RJ | 1 |
| Harada, H; Haratake, J; Hisaoka, M; Matsuyama, A; Shiba, E; Uchihashi, K; Yabuki, K | 1 |
| Matsuda, H; Miyazaki, M; Oka, Y | 1 |
| Del Vecchio, L; Locatelli, F | 1 |
| Ban, S; Imada, H; Kubota, K; Ohshima, S; Satoh, H; Suzuki, S; Ueda, Y | 1 |
| Abraham, JL; Everett, JM; Hoda, RS; Hundemer, GL; Lauwers, GY; Misdraji, J; Sanyal, S; Tolkoff-Rubin, N; Yee, E | 1 |
| Ando, A; Iwamuro, M; Kimura, K; Kusumoto, C; Nada, T; Okada, H; Otsuka, F; Tanaka, T; Urata, H; Yamauchi, K | 1 |
| Balcam, S; Harris, K | 1 |
| Barnett, ME; Hutchison, AJ; Krause, R; Kwan, JT; Siami, GA | 1 |
| Pratt, RD; Smyth, MD | 2 |
| Damment, SJ; Pennick, M | 1 |
| Rodríguez Portillo, M | 1 |
| Torregrosa Prats, V | 1 |
| Shigematsu, T | 4 |
| Behets, GJ; Bervoets, AR; Blust, R; D'Haese, PC; Damment, SJ; Dauwe, S; De Broe, ME; Mubiana, VK; Roels, F; Schryvers, D; Verberckmoes, SC; Yang, Z | 1 |
| Chen, B; D'Haese, PC; Dams, G; De Broe, ME; De Clerck, N; Neven, E; Persy, V; Postnov, A | 1 |
| Hutchison, AJ | 2 |
| Chan, MR; Hinshaw, M; Jaffery, JB; Yevzlin, AS | 1 |
| De Vos, JY; Elseviers, M | 1 |
| Alonso, M; Andrés, E; Ballarín, J; Bover, J; Canal, C; Farré, N; Olaya, MT; Quílez, B | 1 |
| Hutchison, AJ; Mohammed, I | 1 |
| Negi, S; Oda, H; Ohura, M; Sakaguchi, T; Shigematsu, T | 1 |
| Barnett, ME; Hutchison, AJ; Krause, R; Siami, GA | 1 |
| Connor, A; Taylor, JE | 1 |
| Bacchetta, J; Cochat, P; Morel, Y; Nicolino, M; Plotton, I; Ranchin, B; Vial, T | 1 |
| Chantrel, F; Faller, B; Muller, C | 1 |
| Abraham, JL; Davis, RL | 1 |
| Kurz, B; Müller, GA | 1 |
| Krause, R; Nath, SD; Pratt, RD; Ross, EA; Sprague, SM; Zhang, P | 1 |
| Pratt, R; Smyth, M; Wilson, R; Zhang, P | 1 |
| Curran, MP; Robinson, DM | 1 |
| Rees, L; Shroff, RC | 1 |
| Azancot, MA; Bartolomé, J; Sánchez, RR | 1 |
| Borrows, R; Chan, WL; Chapman, E; Collings, K; Dale, C; De Waal, S; Moore, J; Patel, V; Rounsley, K; Tanner, J; Turner, E | 1 |
| Manns, B; Pannu, N; Tonelli, M | 1 |
| Alonso Alvarez, MA; Díez Ojeda, B; Medrano Martínez, S | 1 |
| Auchère, D; Beaune, P; Benchitrit, J; Drüeke, TB; Flinois, JP; Joki, N; Lacour, B; Nikolov, IG; Patey, N; Vicca, S; Ziol, M | 1 |
| Hayashi, H; Kiriyama, T; Kumita, S; Machida, M; Sekine, T; Yamaguchi, H | 1 |
| Blanco Rodríguez, I; Pobes Martínez de Salinas, A; Quiñones Ortiz, L; Suárez Laurés, A | 1 |
| Noto, L | 1 |
| Chacko, Y; Clark, CJ | 1 |
| Epstein, M; Gutiérrez, OM; Isakova, T; Jüppner, H; Keating, LK; Smith, K; Wolf, M | 1 |
| Beer, M; Hofmann, U | 1 |
| Clarkson, MR; Crush, L; Maher, MM; O'Connor, OJ; Plant, W; Shanahan, F | 1 |
| Buscombe, J; Davenport, A; Fürstenberg, A | 1 |
| Hossack, S; Martin, P; Pierce, D; Poole, L; Robinson, A; Smyth, M; Van Heusen, H | 1 |
| Almirall, J; Betancourt, L; Calvet, X; Esteve, V; López, T; Martínez-Ocaña, JC; Ruiz, A; Valenzuela, MP | 1 |
| Damment, S; Lorenzo, V; Rodriguez, M; Secker, R; Shen, V | 1 |
| Palanco, MA; Pérez Alonso, L | 1 |
| Anil, M; Polat, H; Solak, Y; Tonbul, HZ; Turkmen, K | 1 |
| Filiopoulos, V; Hadjiyannakos, D; Koutis, I; Lazarou, D; Trompouki, S; Vlassopoulos, D | 1 |
| Damment, SJ | 1 |
| Arisaka, H; Nakaoka, A; Shigematsu, T; Tokumoto, A | 1 |
| Galán, A; Gonzalez-Casaus, ML; Gonzalez-Parra, E; Martinez-Calero, A; Navas, V; Ortiz, A; Rodriguez, M | 1 |
| Fujii, H; Fujimori, A; Fukagawa, M; Goto, S; Hasegawa, H; Kamae, I; Kim, JI; Komaba, H; Moriwaki, K; Nishi, S; Nishioka, M; Shibuya, K; Shin, J; Taniguchi, M; Yoshiya, K | 1 |
| Negi, S; Shigematsu, T | 1 |
| Ketteler, M; Petermann, AT | 1 |
| Matalon, A; Michelis, MF; Vemuri, N | 1 |
| Moe, SM; Moorthi, RN | 1 |
| Benner, D; Burgess, M; Colson, C; Krishnan, M; Mayne, TJ; Poole, L; Ricketts, K; Smyth, M; Wilson, S | 1 |
| Chantrel, F; Faller, B; Klein, A; Muller, C; Muller, S; Sissoko, A | 1 |
| Akehurst, R; Goldsmith, D; Hodgkins, P; Keith, MS; Park, H; Rascati, KL; Smyth, M | 1 |
| Bonofiglio, R; Coppolino, G; Greco, R; Lofaro, D; Papalia, T; Senatore, M | 1 |
| Dennis, K; Pennick, M; Poole, L; Smyth, M | 1 |
| Keith, MS; Lok, CE; Morton, AR; Soroka, SD; Tolley, K; Vegter, S | 1 |
| Ginard-Vicens, D; Gomila-Roy, GE; Hemfelt-Minobis, A; Khorrami-Minaei, S; Vila-Navarro, S | 1 |
| Eriguchi, M; Kitazono, T; Nakano, T; Tanaka, S; Taniguchi, M; Tsuruya, K; Yamada, S; Yoshida, H | 1 |
| Dellanna, F; Reichel, H; Seibt, F | 1 |
| Choi, HY; Lee, HY; Lee, YK; Shin, SK | 1 |
| Bykadi, S; Carlin, AS; Khan, MA; Shah, RB; Yang, Y; Yu, LX | 1 |
| Albaaj, F; Hutchison, A | 1 |
| Balducci, A; Coen, G; Curic, S; D'Haese, PC; De Broe, ME; Dimkovic, N; Djukanovic, L; Ferreira, A; Freemont, TJ; Hutchison, A; Pejanovic, S; Popovic, M; Sikole, A; Spasovski, GB; Sulkova, S; Sulowicz, W; Swanepoel, C; Torres, A | 1 |
| Amor, J; Palma, A | 1 |
| Bleyer, AJ | 1 |
| Finn, WF; Joy, MS | 2 |
| Al-Baaj, F; Hutchison, AJ; Speake, M | 1 |
| Behets, GJ; D'Haese, PC; De Broe, ME; Verberckmoes, SC | 1 |
| Behets, GJ; Bouillon, R; D'Haese, PC; Damment, SJ; Dams, G; De Broe, ME; Vercauteren, SR | 1 |
| Finn, WF; Hladik, G; Joy, MS | 1 |
| Auchère, D; de Serre Patey, NM; Drüeke, TB; Lacour, B; Lucas, A; Ruellan, N | 1 |
| Behets, GJ; Bervoets, AR; Cox, AG; D'Haese, PC; De Broe, ME; Denton, J; Oste, L; Salomé, M; Verberckmoes, SC | 1 |
| Chen, JB; Chiang, SS; Yang, WC | 1 |
| Aime, S; Canavese, C; Mereu, C; Nordio, M; Sabbioni, E | 1 |
| Behets, GJ; D'Haese, PC; Dams, G; De Broe, ME; Gritters, M | 1 |
| Albaaj, F; Hutchison, AJ | 1 |
| Asmus, G; Backs, W; Hutchison, AJ; Jamar, R; Maes, B; Mohamed, E; Schmieder, R; Vanwalleghem, J; Vosskühler, A | 1 |
| Finch, J; Liapis, H; Slatopolsky, E | 1 |
| Denton, J; Freemont, AJ; Hoyland, JA | 1 |
| Behets, GJ; Bervoets, AR; Blust, R; D'Haese, PC; Dams, G; De Broe, ME; Geryl, H; Marynissen, R; Oste, L | 1 |
| Finn, WF | 1 |
| D'Haese, PC; De Broe, ME; Freemont, T; Gelev, S; Gill, M; Jones, C; Masin-Spasovska, J; Sikole, A; Spasovski, GB; Webster, I | 1 |
| Bellinghieri, G; Calò, LA; Monardo, P; Santoro, D; Savica, V | 1 |
| Cerny, S; Kunzendorf, U | 1 |
| Altmann, P; Barnett, ME; Finn, WF | 1 |
| Ben-Dov, IZ; Galitzer, H; Ilan, Y; Naveh-Many, T; Pappo, O; Silver, J; Sklair-Levy, M | 1 |
| Brancaccio, D; Cozzolino, M | 3 |
| Freemont, AJ | 1 |
| Drüeke, TB; Joki, N; Lacour, B; Nikolov, IG | 1 |
| David, S; Haller, H; Kirchhoff, T; Meier, M | 1 |
| Orita, H; Sakaguchi, T; Shigematsu, T | 1 |
| Bellinghieri, G; Santoro, D; Savica, V | 1 |
| Aime, S; Canavese, C; Stratta, P | 1 |
| Sprague, SM | 1 |
| Daem, AO; Lefèbvre, D; Lemaitre, V; Vrigneaud, L | 1 |
| Forejt, J; Horácková, M; Hrasková, M; Pádr, R; Pafcugová, J; Szabo, M | 1 |
| Negri, AL | 1 |
31 review(s) available for lanthanum carbonate and Chronic Kidney Failure
| Article | Year |
|---|---|
Review of the diagnosis of gastrointestinal lanthanum deposition.
Topics: Atrophy; Gastric Mucosa; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum | 2020 |
A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Topics: Alkaline Phosphatase; Calcium; Chelating Agents; Cholesterol; Humans; Kidney Failure, Chronic; Lanthanum; Parathyroid Hormone; Phosphates; Renal Dialysis; Sevelamer; Treatment Outcome; Triglycerides | 2018 |
Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
Topics: Bone and Bones; Calcium; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Parathyroid Hormone; Phosphates; Vascular Calcification | 2013 |
Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials.
Topics: Calcium; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Placebos; Renal Dialysis; Treatment Outcome | 2014 |
Lanthanum carbonate: safety data after 10 years.
Topics: Adult; Aged; Animals; Biomarkers; Chelating Agents; Clinical Trials, Phase IV as Topic; Databases, Factual; Female; Humans; Hyperphosphatemia; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Safety; Phosphates; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Lanthanum deposition in the gastrointestinal mucosa and regional lymph nodes in dialysis patients: Analysis of surgically excised specimens and review of the literature.
Topics: Aged; Female; Gastric Mucosa; Humans; Kidney Failure, Chronic; Lanthanum; Lymph Nodes; Male; Renal Dialysis; Stomach Neoplasms | 2016 |
Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
Topics: Animals; Biological Availability; Clinical Trials as Topic; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Tissue Distribution | 2008 |
[Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
Topics: Animals; Bone and Bones; Chelating Agents; Chelation Therapy; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hyperphosphatemia; Intestinal Absorption; Kidney Failure, Chronic; Lanthanum; Liver; Nervous System; Phosphorus; Rats; Tissue Distribution | 2008 |
[Lanthanum carbonate in clinical practice].
Topics: Administration, Oral; Chelating Agents; Chelation Therapy; Clinical Trials as Topic; Gastrointestinal Diseases; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Liver; Phosphorus; Tablets | 2008 |
Lanthanum and phosphate: science, policy, and survival.
Topics: Gastrointestinal Tract; Humans; Kidney Failure, Chronic; Lanthanum; Liver; Middle Aged; Minerals; Phosphates | 2009 |
Update on the treatment of chronic kidney disease-mineral and bone disorder.
Topics: Aluminum Compounds; Calcinosis; Calcium Carbonate; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet, Protein-Restricted; Dietetics; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Nephrology; Nutrition Assessment; Nutritive Value; Parathyroidectomy; Patient Care Team; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Vitamin D | 2009 |
Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Topics: Acetates; Administration, Oral; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Chelating Agents; Drug Monitoring; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Magnesium; Nephrology; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
[Advances in blood purification medicine in 2008].
Topics: Anemia; Hematinics; Hemofiltration; Hepatitis C; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Plasma Exchange; Practice Guidelines as Topic; Renal Dialysis | 2009 |
Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Disease Progression; gamma-Glutamyltransferase; Humans; Kidney Failure, Chronic; Lanthanum; Liver; Liver Function Tests; Renal Dialysis | 2009 |
Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.
Topics: Administration, Oral; Adult; Animals; Calcium Carbonate; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Time Factors | 2009 |
Phosphate binders in CKD: chalking out the differences.
Topics: Calcium; Calcium Carbonate; Child; Diet; Humans; Hyperparathyroidism; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vascular Diseases | 2010 |
Oral phosphate binders in patients with kidney failure.
Topics: Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer | 2010 |
Hyperphosphataemia in renal failure: causes, consequences and current management.
Topics: Aluminum; Calcinosis; Calcitriol; Calcium; Cardiovascular Diseases; Chlorides; Epoxy Compounds; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Lanthanum; Magnesium; Phosphates; Polyamines; Polyethylenes; Renal Dialysis; Sevelamer; Uronic Acids; Zirconium | 2003 |
[Management of hyperphosphoremia].
Topics: Calcinosis; Calcium; Case Management; Chelating Agents; Chelation Therapy; Epoxy Compounds; Humans; Hyperparathyroidism, Secondary; Iron; Kidney Failure, Chronic; Lanthanum; Phosphorus; Polyamines; Polyethylenes; Sevelamer | 2003 |
Phosphate binder usage in kidney failure patients.
Topics: Acetates; Aluminum Compounds; Calcium Carbonate; Calcium Compounds; Clinical Trials as Topic; Epoxy Compounds; Humans; Iron Compounds; Ketoglutaric Acids; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Polyethylenes; Renal Dialysis; Sevelamer | 2003 |
Improving phosphate-binder therapy as a way forward.
Topics: Clinical Trials as Topic; Epoxy Compounds; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Polyethylenes; Sevelamer | 2004 |
Lanthanum carbonate: a new phosphate binder.
Topics: Bone and Bones; Buffers; Clinical Trials as Topic; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus; Phosphorus Metabolism Disorders | 2004 |
Blast from the past: the aluminum's ghost on the lanthanum salts.
Topics: Area Under Curve; Chelating Agents; Humans; Kidney Failure, Chronic; Lanthanum; Phosphorus Metabolism Disorders; Renal Dialysis | 2005 |
Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
Topics: Bone and Bones; Calcium; Humans; Kidney Failure, Chronic; Lanthanum; Parathyroid Hormone; Phosphorus Metabolism Disorders; Randomized Controlled Trials as Topic; Renal Dialysis; Safety | 2005 |
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Topics: Acetates; Aluminum Compounds; Bone Diseases, Metabolic; Calcinosis; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Central Nervous System Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Diet, Protein-Restricted; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Sevelamer | 2006 |
Lanthanum carbonate.
Topics: Animals; Bone and Bones; Clinical Trials as Topic; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Trace Elements | 2006 |
[Phosphate binder up to date].
Topics: Aluminum Hydroxide; Calcium Carbonate; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer | 2007 |
Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Topics: Chelating Agents; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Renal Dialysis; Sevelamer | 2007 |
Emerging drugs for hyperphosphatemia.
Topics: Animals; Atherosclerosis; Calcinosis; Calcium Phosphates; Chelating Agents; Drugs, Investigational; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Renal Dialysis; Saliva; Sevelamer; Uremia | 2007 |
A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Topics: Calcium; Chelating Agents; Clinical Trials as Topic; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer; Treatment Outcome | 2007 |
[K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment].
Topics: Calcium; Cinacalcet; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Treatment Outcome | 2007 |
37 trial(s) available for lanthanum carbonate and Chronic Kidney Failure
| Article | Year |
|---|---|
The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; alpha-2-HS-Glycoprotein; Calcium; Calcium Carbonate; Drug Substitution; Female; Fibroblast Growth Factor-23; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Prospective Studies; Renal Dialysis | 2020 |
Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
Topics: Age Factors; Aged; Aorta; Disease Progression; Female; Fibroblast Growth Factor-23; Glomerular Filtration Rate; Heart Disease Risk Factors; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Pulse Wave Analysis; Sex Factors; Treatment Outcome; Vascular Calcification; Vascular Stiffness | 2020 |
Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
Topics: Aged; Calcium; Dose-Response Relationship, Drug; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Dialysis; Time Factors; Treatment Outcome | 2013 |
Study of prolonged administration of lanthanum carbonate in dialysis patients.
Topics: Aged; Calcium; Calcium Carbonate; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome | 2013 |
Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
Topics: Adult; Aged; Calcium; Calcium Carbonate; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2013 |
Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Calcium; Calcium Carbonate; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Medication Adherence; Middle Aged; Parathyroid Hormone; Phosphates; Polyamines; Practice Guidelines as Topic; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors | 2013 |
Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.
Topics: Administration, Oral; Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Mastication; Middle Aged; Phosphorus; Renal Dialysis | 2013 |
The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
Topics: Administration, Oral; Adult; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Polyamines; Renal Dialysis; Risk Assessment; Sevelamer; Severity of Illness Index; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2013 |
Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
Topics: Aged; Calcium; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome | 2014 |
Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Topics: Aged; Calcium; Calcium Carbonate; Chelating Agents; Dose-Response Relationship, Drug; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome | 2014 |
Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Topics: Adult; Aged; Chelating Agents; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Sevelamer; United States | 2014 |
Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Treatment Outcome | 2008 |
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Topics: Antacids; Calcium Carbonate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome | 2008 |
Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Calcium; Chelating Agents; Cross-Over Studies; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
Topics: Adult; Aged; Aged, 80 and over; Chelating Agents; Chelation Therapy; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus, Dietary; Renal Dialysis; Survival Analysis; Time Factors | 2009 |
One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Topics: Abdominal Pain; Adult; Aged; Calcium; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Nausea; Parathyroid Hormone; Phosphates; Renal Dialysis; Treatment Outcome; Vomiting | 2010 |
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
Topics: Aged; Chelating Agents; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Kidney Failure, Chronic; Lanthanum; Middle Aged; Phosphorus Compounds; Phosphorus, Dietary; Pilot Projects | 2011 |
Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients.
Topics: Aged; Asian People; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome; Vitamin D | 2010 |
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.
Topics: Administration, Oral; Adult; Calcitriol; Chelating Agents; Cross-Over Studies; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Polyamines; Sevelamer; Tissue Distribution; Young Adult | 2011 |
Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Topics: Adult; Aged; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis; Young Adult | 2011 |
Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Biomarkers; Cardiovascular Diseases; Chelating Agents; Cost-Benefit Analysis; Drug Costs; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Models, Economic; Phosphorus; Quality-Adjusted Life Years; Renal Dialysis; Time Factors; Treatment Outcome; Young Adult | 2011 |
Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
Topics: Administration, Oral; Adult; Aged; Attitude of Health Personnel; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphates; Phosphorus; Physicians; Tablets; Treatment Outcome | 2011 |
Results of a pilot program to improve phosphorus outcomes in hemodialysis patients.
Topics: Aged; Bone and Bones; Calcium; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Minerals; Nutritional Status; Parathyroid Hormone; Phosphorus; Pilot Projects; Prospective Studies; Renal Dialysis; Serum Albumin | 2012 |
Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.
Topics: Administration, Oral; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus; Phosphorus Compounds; Phosphorus, Dietary; Reference Values; Single-Blind Method; Young Adult | 2012 |
Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Topics: Adult; Calcium; Calcium Carbonate; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Peritoneal Dialysis, Continuous Ambulatory; Phosphates; Prospective Studies; Republic of Korea | 2013 |
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis | 2003 |
Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Topics: Aged; Calcium; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Nausea; Parathyroid Hormone; Peritoneal Dialysis, Continuous Ambulatory; Phosphates; Renal Dialysis; Safety; Treatment Outcome | 2003 |
Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
Topics: Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Time Factors; Titrimetry | 2004 |
Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
Topics: Calcium; Double-Blind Method; Drug Tolerance; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Safety | 2004 |
Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome | 2005 |
A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Topics: Adolescent; Adult; Aged; Calcium; Dose-Response Relationship, Drug; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Phosphorus Metabolism Disorders; Renal Dialysis; Time Factors; Treatment Outcome | 2005 |
Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
Topics: Adult; Aged; Calcium; Calcium Carbonate; Female; Follow-Up Studies; Humans; Hypercalcemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome | 2006 |
The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Calcitriol; Calcium; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus; Renal Dialysis; Treatment Outcome | 2005 |
Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
Topics: Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Renal Dialysis; Treatment Outcome | 2006 |
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Calcifediol; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Follow-Up Studies; Humans; Ilium; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Phosphorus; Renal Dialysis; Treatment Outcome | 2006 |
Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
Topics: Adult; Aged; Cognition; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus Metabolism Disorders; Renal Dialysis | 2007 |
Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Topics: Adult; Aged; Asian People; Calcium; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Dialysis | 2008 |
87 other study(ies) available for lanthanum carbonate and Chronic Kidney Failure
| Article | Year |
|---|---|
Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia.
Topics: Calcium; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Phosphorus; Renal Dialysis | 2022 |
A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.
Topics: Humans; Hyperphosphatemia; Intestinal Obstruction; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Tablets | 2023 |
[Studies of the Various Chronic Kidney Failure Rat Models and Hemodialysis Mini-pig Model for the Evaluation of Anti-hyperphosphatemia Drugs].
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Rats, Wistar; Renal Dialysis; Swine; Swine, Miniature; Therapeutic Equivalency | 2019 |
Massive upper gastrointestinal bleeding due to gastric lanthanosis.
Topics: Gastrointestinal Hemorrhage; Gastroscopy; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Stomach Diseases | 2021 |
PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
Topics: Adenine; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; Ferric Compounds; Kidney Failure, Chronic; Lanthanum; Male; Parathyroid Hormone; Phosphorus; Rats; Sevelamer; Treatment Outcome | 2017 |
Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
Topics: Calcium; Chelating Agents; Drug and Narcotic Control; Health Care Costs; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Medicare Part D; Needs Assessment; Phosphorus; Renal Dialysis; Sevelamer; United States | 2018 |
Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Nutritional Status; Phosphates; Phosphorus; Propensity Score; Renal Dialysis; Treatment Outcome | 2019 |
Lanthanum deposition corresponds to white lesions in the stomach.
Topics: Adult; Aged; Biopsy; Endoscopy, Digestive System; Gastric Mucosa; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Stomach; Stomach Diseases | 2018 |
Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate.
Topics: Adult; Aged; Bone and Bones; Cohort Studies; Female; Fractures, Bone; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Safety; Renal Agents; Renal Dialysis; Treatment Outcome; United States | 2018 |
Lanthanum phosphate binder-induced iron deficiency anaemia.
Topics: Aged; Anemia, Iron-Deficiency; Gastric Mucosa; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male | 2019 |
An incidental finding of metallic objects in a patient with chronic renal failure.
Topics: Administration, Oral; Aged; Foreign-Body Reaction; Humans; Incidental Findings; Kidney Failure, Chronic; Kidney Transplantation; Lanthanum; Male; Tomography, X-Ray Computed | 2019 |
Lanthanum deposition in the gastric mucosa in a patient treated with haemodialysis.
Topics: Aged; Endoscopy, Digestive System; Gastric Mucosa; Histiocytes; Humans; Kidney Failure, Chronic; Lanthanum; Male | 2019 |
Fecalith formation and colonic perforation after lanthanum carbonate granules administration.
Topics: Colonic Diseases; Dose-Response Relationship, Drug; Fecal Impaction; Humans; Intestinal Perforation; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Tomography, X-Ray Computed | 2014 |
A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Topics: Acetates; Adult; Biomarkers; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Female; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Polyamines; Renal Dialysis; Retrospective Studies; Sevelamer; Time Factors; Treatment Outcome | 2014 |
A comparison of the long-term effects of lanthanum carbonate and calcium carbonate on the course of chronic renal failure in rats with adriamycin-induced nephropathy.
Topics: Animals; Blood Pressure; Calcium Carbonate; Disease Models, Animal; Doxorubicin; Glucuronidase; Kidney Failure, Chronic; Kidney Function Tests; Klotho Proteins; Lanthanum; Male; Rats; Time Factors | 2014 |
Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules.
Topics: Adult; Aged; Aged, 80 and over; Chemistry, Pharmaceutical; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Medication Adherence; Middle Aged; Patient Preference; Phosphorus; Renal Dialysis; Surveys and Questionnaires; Tablets | 2014 |
[Does the presence of contrast material in the digestive tract mean prior barium ingestion?].
Topics: Aged, 80 and over; Barium Sulfate; Constipation; Contrast Media; Eating; Gastrointestinal Tract; Humans; Kidney Failure, Chronic; Lanthanum; Male; Radiography | 2015 |
Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
Topics: Adult; Costs and Cost Analysis; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Retrospective Studies; Sevelamer; Tablets | 2014 |
Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.
Topics: Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model.
Topics: Adenine; Animal Feed; Animals; Calcinosis; Calcium Carbonate; Cellular Senescence; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Inflammation; Kidney; Kidney Failure, Chronic; Lanthanum; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Phosphates; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction; Uremia; Vascular Calcification | 2015 |
Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Topics: Bone and Bones; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Renal Dialysis; Time Factors | 2015 |
Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Topics: Animals; Body Weight; Disease Models, Animal; Drug Combinations; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Homeostasis; Kidney Failure, Chronic; Lanthanum; Male; Mortality; Phosphates; Rats, Wistar; Sevelamer; Sucrose; Vascular Calcification | 2015 |
Specific Accumulation of Lanthanum Carbonate in the Gastric Mucosal Histiocytes in a Dialysis Patient.
Topics: Biopsy; Carcinoma, Renal Cell; Gastroscopy; Histiocytes; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Kidney Neoplasms; Lanthanum; Male; Microscopy, Electron, Scanning; Middle Aged; Nephrectomy; Renal Dialysis; Stomach Diseases; Tomography, X-Ray Computed | 2015 |
White Gastric Mucosa in a Dialysis Patient.
Topics: Administration, Oral; Aged; Biopsy; Chelating Agents; Endoscopy, Digestive System; Gastric Mucosa; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Microscopy, Electron, Scanning; Renal Dialysis; Spectrometry, X-Ray Emission | 2016 |
Lanthanum carbonate has a radiopaque appearance on the plain abdominal radiography.
Topics: Abdomen; Abdominal Pain; Aged, 80 and over; Constipation; Female; Humans; Kidney Failure, Chronic; Lanthanum; Radiography, Abdominal | 2016 |
Did Lanthanum Carbonate Improve Prognosis in Patients Requiring Chronic Hemodialysis in the Kawashima Study?
Topics: Calcium Carbonate; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Prognosis; Renal Dialysis | 2016 |
Haemodialysis: Intradialytic meals: addressing a neglected problem.
Topics: Combined Modality Therapy; Diet, High-Protein; Energy Intake; Humans; Kidney Failure, Chronic; Lanthanum; Malnutrition; Meals; Renal Dialysis; Treatment Outcome | 2017 |
Gastric mucosal status susceptible to lanthanum deposition in patients treated with dialysis and lanthanum carbonate.
Topics: Aged; Aged, 80 and over; Biopsy; Female; Gastric Mucosa; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Stomach Diseases | 2017 |
Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract.
Topics: Adult; Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Upper Gastrointestinal Tract | 2017 |
Lanthanum Deposition in the Stomach: Usefulness of Scanning Electron Microscopy for Its Detection.
Topics: Aged; Endoscopy, Digestive System; Female; Gastric Mucosa; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Microscopy, Electron, Scanning | 2017 |
A case of lanthanum carbonate ingestion thought to be phlebosclerotic colitis on CT imaging and abdominal radiograph.
Topics: Aged, 80 and over; Colitis; Diagnosis, Differential; Humans; Kidney Failure, Chronic; Lanthanum; Male; Radiography, Abdominal; Tomography, X-Ray Computed | 2017 |
Letter regarding 'Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate'.
Topics: Chelating Agents; Contraindications; Contrast Media; Gadolinium; Humans; Kidney Diseases; Kidney Failure, Chronic; Lanthanum; United States; United States Food and Drug Administration; Uremia | 2008 |
Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure.
Topics: Animals; Bile Canaliculi; Brain; Intestinal Absorption; Kidney Failure, Chronic; Lanthanum; Liver; Lysosomes; Male; Myocardium; Rats; Rats, Inbred Strains; Tissue Distribution; Uremia | 2009 |
Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.
Topics: Animals; Arteries; Bone and Bones; Calcinosis; Chondrogenesis; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Osteogenesis; Phosphates; Rats; Rats, Wistar; Vascular Diseases | 2009 |
Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy.
Topics: Calciphylaxis; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lanthanum; Liver Transplantation; Male; Middle Aged; Renal Dialysis | 2008 |
The use of phosphate binders: data from contributors to the European Practice Database.
Topics: Acetates; Aluminum Compounds; Analysis of Variance; Calcium Carbonate; Calcium Compounds; Chelating Agents; Cross-Sectional Studies; Databases, Factual; Dietetics; Drug Utilization; Europe; Health Care Surveys; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Nephrology; Polyamines; Practice Patterns, Physicians'; Renal Dialysis; Sevelamer; Surveys and Questionnaires; Vitamin D | 2009 |
An unusual abdominal radiograph.
Topics: Abdominal Pain; Colon; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphate-Binding Proteins; Radiography | 2009 |
Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism.
Topics: Child, Preschool; Cinacalcet; Drug Approval; Drug Labeling; Hepatocyte Nuclear Factor 1-beta; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Lanthanum; Male; Mutation; Naphthalenes; Puberty, Precocious; Testosterone; Treatment Outcome | 2009 |
A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report.
Topics: Aged; Confusion; Female; Humans; Kidney Failure, Chronic; Lanthanum; Renal Dialysis | 2009 |
Lanthanum deposition in a dialysis patient.
Topics: Adult; Female; Humans; Kidney Failure, Chronic; Lanthanum; Lymph Nodes; Mesentery; Renal Dialysis | 2009 |
[Acute abdominal pain in a 70-year-old patient on hemodialysis].
Topics: Abdominal Pain; Aged; Colectomy; Colon; Diabetic Nephropathies; Diagnosis, Differential; Foreign Bodies; Humans; Hyperphosphatemia; Ischemia; Kidney Failure, Chronic; Lactic Acid; Lanthanum; Male; Mastication; Radiography; Renal Dialysis; Tablets | 2009 |
A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report.
Topics: Confusion; Humans; Kidney Failure, Chronic; Lanthanum; Renal Dialysis | 2009 |
[Hyperamylasaemia and broncoaspiration associated with lanthanum carbonate].
Topics: Fatal Outcome; Female; Humans; Hyperamylasemia; Kidney Failure, Chronic; Lanthanum; Middle Aged; Respiratory Aspiration | 2009 |
Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
Topics: Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Treatment Outcome | 2010 |
[Radiology image of lanthanum carbonate].
Topics: Abdominal Pain; Artifacts; Chelating Agents; Chelation Therapy; Colon; Diabetic Nephropathies; Diagnosis, Differential; Diverticulitis, Colonic; Diverticulosis, Colonic; Fever; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Tomography, X-Ray Computed | 2010 |
Tissue accumulation of lanthanum as compared to aluminum in rats with chronic renal failure--possible harmful effects after long-term exposure.
Topics: Aluminum; Aluminum Hydroxide; Animals; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Liver; Male; Organ Size; Rats; Rats, Sprague-Dawley | 2010 |
Beam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysis.
Topics: Aged; Artifacts; Diagnosis, Differential; Foreign Bodies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Renal Dialysis; Tomography, X-Ray Computed | 2010 |
[Intestinal pseudo-occlusion due to lanthanum carbonate].
Topics: Aged; Chelating Agents; Chelation Therapy; Chronic Kidney Disease-Mineral and Bone Disorder; Colonic Diseases; Humans; Hyperphosphatemia; Intestinal Pseudo-Obstruction; Ischemia; Kidney; Kidney Failure, Chronic; Lanthanum; Laparotomy; Male; Phosphates; Radiography; Renal Dialysis | 2010 |
Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
Topics: Acetates; Aged; Aged, 80 and over; Calcium Carbonate; Calcium Compounds; Chelating Agents; Humans; Kidney Failure, Chronic; Lanthanum; Middle Aged; New York; Nutritional Status; Phosphates; Phosphorus; Polyamines; Renal Dialysis; Retrospective Studies; Serum Albumin; Sevelamer; Treatment Outcome | 2011 |
Christmas lights in the gastrointestinal tract.
Topics: Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Radiography, Abdominal | 2010 |
Colonic opacification in a patient with end-stage kidney disease.
Topics: Abdominal Pain; Aged; Colon; Female; Humans; Kidney Failure, Chronic; Lanthanum; Peritoneal Dialysis; Tomography, X-Ray Computed | 2010 |
Perplexing plain abdominal x-ray. Radiographic opacities were due to the lanthanum.
Topics: Abdominal Pain; Barium Sulfate; Colon; Contrast Media; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Radiography | 2011 |
Overestimation of lumbar spine calcium with dual energy X-ray absorptiometry scanning due to the prescription of lanthanum carbonate in patients with chronic kidney disease.
Topics: Absorptiometry, Photon; Bone Density; Diagnostic Errors; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis | 2010 |
Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
Topics: Aged; Chelating Agents; Dyspepsia; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphates; Prospective Studies; Renal Dialysis | 2012 |
Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.
Topics: Animals; Bone Diseases; Calcification, Physiologic; Calcium; Kidney Failure, Chronic; Lanthanum; Male; Minerals; Phosphorus; Rats; Rats, Wistar | 2011 |
[Lanthanum carbonate: a novel explanation of a common x-ray image].
Topics: Aged; Colon; Humans; Kidney Failure, Chronic; Lanthanum; Male; Radiography | 2011 |
An unusual hurdle to renal transplantation: speckled abdominal opacities induced by lanthanum carbonate.
Topics: Enema; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lanthanum; Middle Aged; Radiography, Abdominal | 2010 |
Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.
Topics: Acidosis; Aged; Dialysis Solutions; Female; Humans; Hyperkalemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer | 2011 |
Pharmacology of the phosphate binder, lanthanum carbonate.
Topics: Aluminum Hydroxide; Animals; Calcium; Calcium Carbonate; Chelating Agents; Dogs; Drug Evaluation, Preclinical; Feces; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Mice; Phosphates; Phosphorus Radioisotopes; Polyamines; Rats; Rats, Sprague-Dawley; Sevelamer | 2011 |
Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.
Topics: Aged; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Lanthanum; Longitudinal Studies; Male; Phosphorus; Prognosis; Prospective Studies | 2011 |
Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
Topics: Adult; Aged; Antacids; Calcium; Calcium Carbonate; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Treatment Outcome; Young Adult | 2012 |
Phosphate and FGF23 in early CKD: on how to tackle an invisible foe.
Topics: Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus | 2011 |
CKD-mineral and bone disorder: core curriculum 2011.
Topics: Bone Diseases; Calcinosis; Calciphylaxis; Calcitriol; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Lanthanum; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2011 |
Radio-opaque fecal impaction and pseudo-occlusion in a dialyzed patient taking lanthanum carbonate.
Topics: Aged; Fecal Impaction; Humans; Kidney Failure, Chronic; Lanthanum; Male; Radiography; Renal Dialysis | 2012 |
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
Topics: Cardiovascular Diseases; Chelating Agents; Cost-Benefit Analysis; Cross-Over Studies; Databases, Factual; Economics, Pharmaceutical; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Polyamines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Sevelamer; United States | 2011 |
Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
Topics: Aged; Chelating Agents; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Polyamines; Renal Dialysis; Sevelamer | 2011 |
Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Topics: Canada; Chelating Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Follow-Up Studies; Hospitalization; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Markov Chains; Models, Economic; Polyamines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer; Survival Rate; Treatment Outcome | 2012 |
Unusual image of lanthanum carbonate in the abdominal radiograph.
Topics: Abdominal Pain; Aged; Appendix; Colon; Diarrhea; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Radiography | 2012 |
Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.
Topics: Adult; Diabetic Nephropathies; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Multivariate Analysis; Nutritional Status; Parathyroid Hormone; Peritoneal Dialysis; Phosphates; Retrospective Studies | 2012 |
Efficacy and safety of lanthanum carbonate in German patients on dialysis.
Topics: Adult; Aged; Calcium; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Product Surveillance, Postmarketing; Prospective Studies; Renal Dialysis; Tablets | 2012 |
Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.
Topics: Humans; Hydrogen-Ion Concentration; Kidney Failure, Chronic; Kinetics; Lanthanum; Phosphates; Tablets | 2013 |
Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Diseases; Bone Remodeling; Calcium; Creatinine; Eating; Kidney Failure, Chronic; Lanthanum; Male; Osteoblasts; Osteocalcin; Parathyroid Hormone; Phosphates; Phosphorus; Rats; Rats, Wistar; Vitamin D | 2004 |
Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.
Topics: Administration, Oral; Animals; Body Weight; Intestine, Small; Kidney; Kidney Failure, Chronic; Lanthanum; Male; Organ Size; Rats; Rats, Sprague-Dawley | 2005 |
Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
Topics: Administration, Oral; Animals; Bone and Bones; Bone Density; Chronic Kidney Disease-Mineral and Bone Disorder; Kidney Failure, Chronic; Lanthanum; Male; Phosphates; Rats; Rats, Wistar; Spectrometry, X-Ray Emission; Tissue Distribution | 2005 |
Effects of efficient phosphate binding on bone in chronic renal failure rats.
Topics: Animals; Bone and Bones; Bone Density; Disease Models, Animal; Epoxy Compounds; Kidney Failure, Chronic; Kidney Function Tests; Lanthanum; Male; Nephrectomy; Osteoporosis; Phosphates; Polyamines; Polyethylenes; Probability; Rats; Rats, Wistar; Sensitivity and Specificity; Sevelamer; Statistics, Nonparametric | 2005 |
Progressive accumulation of lanthanum in the liver of normal and uremic rats.
Topics: Animal Feed; Animals; Creatinine; Female; Femur; Hyperparathyroidism, Secondary; Kidney; Kidney Failure, Chronic; Lanthanum; Liver; Phosphorus; Rats; Rats, Sprague-Dawley; Uremia | 2005 |
Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats.
Topics: Animals; Bone and Bones; Bone Density; Calcification, Physiologic; Calcium; Kidney Failure, Chronic; Lanthanum; Male; Phosphates; Rats; Rats, Wistar | 2006 |
Phosphate binders.
Topics: Acetates; Calcium Carbonate; Calcium Compounds; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer | 2006 |
Images in clinical medicine. Radiographic appearance of lanthanum.
Topics: Aged, 80 and over; Colon; Humans; Kidney Failure, Chronic; Lanthanum; Male; Phosphates; Phosphorus Metabolism Disorders; Radiography | 2006 |
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats.
Topics: Animals; Biopsy; Disease Models, Animal; Disease Progression; Gene Expression; Kidney Failure, Chronic; Lanthanum; Liver; Magnetic Resonance Imaging; Male; Parathyroid Hormone; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; RNA; Uremia | 2007 |
Lanthanum carbonate--new data on parathyroid hormone control without liver damage.
Topics: Humans; Kidney Failure, Chronic; Lanthanum; Nephrectomy; Parathyroid Hormone; Phosphorus Metabolism Disorders; Treatment Outcome | 2007 |
Lanthanum carbonate, body lanthanum accumulation and potential liver toxicity.
Topics: Animals; Kidney Failure, Chronic; Lanthanum; Liver; Organ Size; Rats | 2007 |
Heavy metal--rely on gut feelings: novel diagnostic approach to test drug compliance in patients with lanthanum intake.
Topics: Colon; Feces; Female; Humans; Kidney Failure, Chronic; Lanthanum; Middle Aged; Patient Compliance; Phosphates; Radiography, Abdominal; Renal Dialysis; Tomography, X-Ray Computed | 2007 |
Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
Topics: Atherosclerosis; Calcinosis; Calcium Phosphates; Chelating Agents; Drugs, Investigational; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Renal Dialysis; Sevelamer; Uremia | 2007 |
Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate.
Topics: Chelating Agents; Contraindications; Fibrosis; Gadolinium; Humans; Kidney Diseases; Kidney Failure, Chronic; Lanthanum; Skin Diseases; United States; United States Food and Drug Administration; Uremia | 2007 |
[Radiographic characteristics of lanthanum carbonate absorption].
Topics: Aged; Chelating Agents; Female; Humans; Hyperphosphatemia; Intestinal Absorption; Intestinal Diseases; Kidney Failure, Chronic; Lanthanum; Radiography | 2008 |
Radio-opaque appearance of lanthanum carbonate in a patient with chronic renal failure.
Topics: Aged; Contrast Media; Humans; Kidney Failure, Chronic; Lanthanum; Male; Renal Dialysis; Tomography, X-Ray Computed; Ureterolithiasis | 2008 |